Get the Stockscreener App
1,215.02
1.37%
-16.92
Pre-market:
1212.76
-2.26
-0.19%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,215.02, with a volume of 2.09M.
It is down -1.37% in the last 24 hours and up +2.22% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,231.94
Open:
$1230.65
24h Volume:
2.09M
Relative Volume:
0.70
Market Cap:
$1.08T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
43.74
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+8.90%
1M Performance:
+2.22%
6M Performance:
+19.68%
1Y Performance:
+91.28%
1-Day Range:
$1,209.53
$1,238.00
1-Week Range:
$1,136.74
$1,238.00
52-Week Range:
$629.40
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,215.02 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.80 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.09 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.42 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.61 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Lilly comes down hard on retatrutide black marketeers - FirstWord Pharma
Tema ETFs LLC Has $29.99 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly escalates fight against black market weight-loss medicines - BusinessLine
Lilly Escalates Its Fight Against Black Market Weight-Loss Shots - Bloomberg.com
Berenberg cuts Novo Nordisk as Lilly’s obesity dominance limits upside By Investing.com - Investing.com Australia
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - Reuters
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market - PR Newswire
Eli Lilly official, others explain what brought their companies to Alabama - Decatur Daily
Better Buy: Eli Lilly vs. Novo Nordisk - finance.yahoo.com
Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Down 1.5% After Insider Selling - MarketBeat
Eli Lilly's Weight-Loss Pill Wins U.K. Approval - Briefs Finance
Why Is Eli Lilly (NYSE:LLY) the Healthcare Name in Focus After Its Obesity Pill Nod? - Kalkine Media
Eli Lilly Just Made a Huge Bet on Psychedelics for Mental Health - Flow Space
Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles - Investing News Network
Eli Lilly (NYSE:LLY) Oncology Push Opens A Bigger Story - Kalkine Media
Lilly's Foundayo Pill Lands First European Approval, Challenging Novo's Wegovy in UK - finance.biggo.com
Lilly Takes Its Weight-Loss Pill Battle Overseas - GuruFocus
ATAI Beckley earnings on deck as investors eye Lilly deal By Investing.com - Investing.com South Africa
MedPal AI eyes private GLP-1 market after UK authorises Eli Lilly weight-loss pill - Yahoo Finance UK
Eli Lilly commits to Veeva Vault CRM globally By Investing.com - Investing.com Canada
UK first in Europe to approve Eli Lilly oral weight loss drug - The Economic Times
Eli Lilly commits to Veeva Vault CRM globally - Investing.com
Veeva Vault CRM Selected by Eli Lilly and Company - PR Newswire UK
Eli Lilly and Company $LLY Shares Sold by Handelsbanken Fonder AB - MarketBeat
UK approves Eli Lilly’s oral weight loss pill orforglipron - Investing.com
KMG Fiduciary Partners LLC Sells 4,785 Shares of Eli Lilly and Company $LLY - MarketBeat
REGMedpal AI PLCUK Authorises Eli Lilly's Once Daily GLP-1 Pill - TradingView
Foundayo: The new weight loss pill approved for the UK - The Independent
LLY Looks 18.0% Undervalued on GF Value™ as Foundayo Gains U.K. Approval - GuruFocus
Eli Lilly and Company $LLY Shares Acquired by E. Ohman J or Asset Management AB - MarketBeat
Constitution Capital LLC Buys 7,711 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Co (LLY) Stock Up 3.9% and Still Undervalued -- GF Score: 92/100 - GuruFocus
Eli Lilly and Company (NYSE:LLY) Trading 3.7% Higher After Analyst Upgrade - MarketBeat
Eli Lilly's weight-loss pill secures first European nod in Britain - Reuters
Eli Lilly and Co Stock (LLY) Moved Up by 3.48% on Aug 10: Drivers Behind the Movement - TradingKey
Eli Lilly's new weight-loss pill authorised by MHRA - thepharmacist.co.uk
New weight-loss pill approved for use in UK - BBC
Why Eli Lilly (NYSE:LLY) Just Became the World's Largest Healthcare Name? - Kalkine Media
Eli Lilly Upgraded, Best Buy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Did Eli Lilly (NYSE:LLY) Jump After Its Latest Quarterly Report? - Kalkine Media
Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup - ChartMill
Eli Lilly and Company $LLY Shares Sold by StoneCrest Wealth Management Inc. - MarketBeat
How to Trade Eli Lilly After Q2 Earnings Beat - Admirals
Multibillion-dollar construction projects take root in Milwaukee-area: The List - The Business Journals
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? - AOL.com
Eli Lilly and Company Q2 Earnings Call Highlights - MarketBeat
Eli Lilly and Company Just Recorded A 11% Revenue Beat: Here's What Analysts Think - 富途牛牛
Gradient Investments LLC Boosts Holdings in Eli Lilly and Company $LLY - MarketBeat
Thurston Springer Miller Herd & Titak Inc. Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Teamwork Financial Advisors LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hakim Anat | EVP, GC & Secretary |
Aug 07 '26 |
Sale |
1,190.00 |
5,000 |
5,950,000 |
11,875 |
0.77%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):